Overview

Odiparcil QT Definitive Study

Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
0
Participant gender:
All
Summary
This study is being completed to demonstrate the lack of effect of repeat dosing with Odiparcil on the QTc interval.
Phase:
Phase 1
Accepts Healthy Volunteers?
Accepts Healthy Volunteers
Details
Lead Sponsor:
GlaxoSmithKline
Criteria
Inclusion:

- Healthy volunteers

Exclusion:

- Cardiac abnormalities

- Hepatic or renal insufficiency

- Anti-coagulant medications

- Bleeding history